Waters Corporation Completes Transformational Combination with BD Biosciences & Diagnostic Solutions
Waters Corporation has officially finalized its previously announced combination with the Biosciences and Diagnostic Solutions businesses of Becton, Dickinson and Company, creating a newly expanded global leader in life sciences, diagnostics, and advanced analytical technologies. The completion of this strategic transaction marks a defining milestone for Waters as it broadens its scientific reach, enhances its technology portfolio, and strengthens its long-term financial outlook within highly regulated and innovation-driven markets. By uniting complementary expertise across chemistry, biology, and physics, the combined organization is positioned to accelerate breakthroughs in therapeutic development, clinical diagnostics, food safety, and environmental testing while delivering sustained value to customers, shareholders, and the broader healthcare ecosystem. The company also announced a significant governance update alongside the transaction’s closing, reinforcing its commitment to scientific excellence and forward-looking leadership as it enters this next phase of global growth.
Appointment of Renowned Genome Scientist Claire M. Fraser to the Waters Board
As part of the broader transformation, Waters confirmed the appointment of Claire M. Fraser, Ph.D., to its Board of Directors, expanding the board’s total membership to eleven. Dr. Fraser is internationally recognized for her pioneering contributions to genomics, infectious disease research, and molecular diagnostics, bringing more than three decades of leadership experience guiding major scientific institutions and multidisciplinary research initiatives. She most recently served as Director of The Institute for Genome Sciences at the University of Maryland School of Medicine, an organization she founded in 2007, where she also held professorships in medicine as well as microbiology and immunology. Her academic background includes a Bachelor of Science in Biology from Rensselaer Polytechnic Institute and a Ph.D. in Pharmacology from the State University of New York at Buffalo. Through her appointment, Waters strengthens its governance with deep scientific insight, translational research expertise, and strategic understanding of emerging diagnostic technologies that are increasingly shaping the future of precision medicine and global health.
Leadership Perspective on Strategic Growth and Scientific Innovation
Waters Chairman Flemming Ørnskov emphasized the importance of both the transaction and Dr. Fraser’s appointment, describing the moment as a major step forward in the company’s evolution. He highlighted Dr. Fraser’s global reputation in genomics and infectious diseases, noting that her experience will help guide Waters through its next era of innovation, operational expansion, and value creation. From the executive leadership perspective, President and Chief Executive Officer Udit Batra described the combination with BD’s Biosciences and Diagnostic Solutions units as a pivotal turning point that unites world-class scientific capabilities and long histories of technological advancement. He underscored the company’s clear priorities moving forward: addressing unmet customer needs, generating durable shareholder returns, and delivering solutions that improve health outcomes worldwide. According to Batra, the integration of complementary product platforms and a shared culture rooted in discovery and innovation will enable the combined organization to accelerate scientific progress and expand its influence across rapidly evolving healthcare and research landscapes.
Establishment of Four Strategic Divisions to Drive Focused Growth
With the transaction now complete, Waters has reorganized its structure into four dedicated divisions designed to sharpen operational focus, support regulated high-volume testing environments, and expand into adjacent high-growth markets. This divisional framework aligns specialized scientific teams with targeted application areas spanning therapeutic development, diagnostics, materials science, and environmental and food analysis. The structure reflects Waters’ long-term strategy of combining analytical precision with biological insight to serve both research and clinical communities while maintaining strong compliance, scalability, and innovation capabilities. Each division integrates legacy strengths from Waters and BD, creating unified platforms capable of accelerating product development, improving laboratory efficiency, and advancing next-generation diagnostic and analytical methodologies across global markets.
Waters Analytical Sciences Strengthens Leadership in Separations and Molecular Characterization
The Waters Analytical Sciences division encompasses the company’s core technologies in separations science and physical molecular characterization, bringing together instruments, consumables, services, and compliant informatics solutions historically associated with Waters’ analytical leadership. This division includes liquid chromatography systems, mass spectrometry platforms, ultraviolet detection, light scattering technologies, and particle analysis tools that are essential for pharmaceutical research, biopharmaceutical manufacturing, and regulatory-compliant quality control. By consolidating these capabilities, Waters enhances its ability to deliver integrated analytical workflows that improve sensitivity, reproducibility, and throughput in complex testing environments. The division also reinforces the company’s foundational role in supporting both large-molecule biologics and small-molecule therapeutics, ensuring researchers and manufacturers can meet stringent regulatory requirements while accelerating time to discovery and commercialization.
Waters Biosciences Expands Capabilities in Cellular and Single-Cell Analysis
Formed from the former BD Biosciences business, the Waters Biosciences division focuses on advanced biological analysis technologies spanning cellular sorting, flow cytometry instrumentation, reagent development, and emerging single-cell multiomics solutions. These tools enable scientists to explore cellular heterogeneity, immune system dynamics, and disease mechanisms with unprecedented precision, supporting research in oncology, immunology, infectious diseases, and regenerative medicine. Integration within Waters provides expanded opportunities to connect biological insights with analytical chemistry platforms, potentially enabling more comprehensive end-to-end research workflows. The division is positioned to play a critical role in the growing field of precision medicine, where understanding cellular behavior at the single-cell level is increasingly essential for developing targeted therapies and personalized diagnostic strategies.
Waters Advanced Diagnostics Enhances Clinical and Molecular Testing Solutions
The Waters Advanced Diagnostics division merges BD’s Diagnostic Solutions portfolio with the legacy Waters Clinical Business to create a unified platform dedicated to high-value diagnostic workflows in regulated healthcare settings. Its offerings include microbiology systems, molecular diagnostic technologies, LC-MS-based multiplex testing, laboratory automation, and point-of-care testing solutions designed to deliver rapid, accurate clinical insights. This integration strengthens Waters’ presence in clinical laboratories and hospital environments, expanding beyond research instrumentation into routine patient care and disease detection. By combining analytical chemistry expertise with diagnostic innovation, the division aims to support earlier detection of disease, improved treatment monitoring, and more efficient healthcare delivery. The growing demand for molecular diagnostics, particularly in infectious disease surveillance and personalized medicine, positions this division as a major driver of long-term growth.
Waters Materials Sciences Supports Innovation Across Advanced Industrial Applications
The Waters Materials Sciences division, derived from the former TA business, focuses on characterization technologies such as thermal analysis, rheology, and microcalorimetry that are widely used in batteries, electronics, polymers, and pharmaceutical materials research. These techniques help scientists understand material stability, performance, and structural behavior under varying environmental and mechanical conditions. As industries pursue next-generation energy storage, lightweight electronics, and advanced drug formulations, demand for precise materials characterization continues to rise. By integrating this expertise within the broader Waters ecosystem, the company strengthens its ability to serve both life sciences and high-technology manufacturing sectors, reinforcing diversification and resilience across multiple innovation-driven markets.
Reverse Morris Trust Transaction Structure and Shareholder Ownership
The combination between Waters and BD’s Biosciences and Diagnostic Solutions businesses was executed through a Reverse Morris Trust structure, a transaction mechanism commonly used to achieve tax-efficient mergers involving corporate spin-offs. Under this arrangement, BD separated the relevant businesses into an independent entity, which subsequently merged with a wholly owned subsidiary of Waters and became part of the combined organization. Following completion, legacy Waters shareholders collectively hold approximately 60.8 percent of the new company on a fully diluted basis, while BD shareholders own about 39.2 percent. BD investors received roughly 0.135 shares of Waters common stock for each BD share held as of the February 5, 2026, record date, with cash distributed in place of fractional shares. This ownership distribution reflects the relative scale and contribution of each party while enabling both shareholder groups to participate in the anticipated long-term value creation of the combined enterprise.
Advisory Support and Legal Guidance Behind the Transaction
The successful completion of the transaction relied on extensive financial and legal expertise, with Barclays serving as financial advisor to Waters and Kirkland & Ellis LLP acting as lead legal counsel. Their roles included structuring the deal, ensuring regulatory compliance, advising on valuation and shareholder considerations, and guiding the complex integration process. Such advisory collaboration is critical in large-scale life sciences transactions, where intellectual property, regulatory frameworks, and global operational footprints must be carefully aligned to achieve strategic objectives while minimizing risk.
Positioning for Long-Term Impact in Global Life Sciences and Diagnostics
With the integration finalized, Waters emerges as a more diversified and technologically comprehensive organization spanning analytical instrumentation, biological research tools, clinical diagnostics, and materials science solutions. The company’s expanded capabilities position it to address some of the most pressing scientific and healthcare challenges, from accelerating drug discovery to improving disease detection and ensuring environmental and food safety. Leadership confidence, strengthened governance, and a clearly defined divisional structure collectively signal a long-term strategy centered on innovation, operational excellence, and sustained financial performance. As global demand for advanced diagnostics, precision therapeutics, and high-performance analytical technologies continues to grow, Waters’ transformation through this combination represents not only a corporate milestone but also a significant development within the broader life sciences industry.
Source Link:https://ir.waters.com/
